Function Oncology, based in San Diego, CA, operates a CRISPR-powered personalized functional genomics platform that modulates genes directly in patient clinical samples to measure gene function rather than just sequence. The platform enables personalized, comprehensive profiling of each patient’s tumor to uncover drug target dependencies that conventional genomic profiling can miss. Patient-specific insights may be used to produce tailored treatment strategies and, in aggregate, to power the development of new therapies against known or novel cancer drivers. The company is led by co-founder and CEO Srinath Sampath, M.D., Ph.D., MPhil, with co-founders Srihari Sampath and Christian Schmedt and senior leaders including Yali Li and Ryan Pinto. Advisors include William Hahn and David B. Solit, and the board features investors and industry leaders such as Vineeta Agarwala and Steve Kafka. Financially, the company recently completed a material financing event (Series A) as described below.

Total raised

$28M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2023